How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart [Yahoo! Finance]
Dianthus Therapeutics, Inc. (DNTH)
Company Research
Source: Yahoo! Finance
polyneuropathy (CIDP), after meeting interim responder goals ahead of schedule. At the same time, the FDA agreed to broaden clinical development changes for claseprubart, covering screening, lab work, and autoimmune safety monitoring, across all current and future studies, potentially simplifying the path for this program. With claseprubart's CAPTIVATE trial advancing earlier than planned, we'll now examine how this regulatory momentum influences Dianthus Therapeutics' investment narrative. Outshine the giants: these 22 early-stage AI stocks could fund your retirement What Is Dianthus Therapeutics' Investment Narrative? To own Dianthus Therapeutics, you have to believe claseprubart can convert its neuromuscular pipeline into a meaningful, de-risked commercial story before the cash burn and dilution bite too hard. The early “GO” decision in CAPTIVATE and the FDA's agreement to streamline development tilt the near-term catalyst mix more toward clinical execution and regulatory
Show less
Read more
Impact Snapshot
Event Time:
DNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNTH alerts
High impacting Dianthus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DNTH
News
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Dianthus Therapeutics CFO Sells $9.5 Million in Stock [Yahoo! Finance]Yahoo! Finance
- Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- Dianthus Therapeutics (DNTH) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $135.00 price target on the stock.MarketBeat
- Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP [Yahoo! Finance]Yahoo! Finance
DNTH
Earnings
- 3/9/26 - Miss
DNTH
Sec Filings
- 4/1/26 - Form 4
- 4/1/26 - Form 4
- 3/31/26 - Form 144
- DNTH's page on the SEC website